Analyst firms · Oppenheimer · BMRN
Oppenheimer BMRN price target and rating history
BioMarin Pharmaceutical Inc. (BMRN) · Health Care
Oppenheimer rates BioMarin Pharmaceutical Inc. (BMRN) Outperform with a $98 price target, as of its latest action on Feb 24, 2025. It has published 3 rating actions on BMRN since October 2022, including 2 upgrades and 1 downgrade. Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.
- Current rating
- Outperform
- Price target
- $98
- Median target, all firms
- $88
- Actions on BMRN
- 3
Oppenheimer price target on BMRN
Every Oppenheimer rating on BMRN
- Feb 24, 2025
- Feb 22, 2023
- Oct 31, 2022
How other firms rate BMRN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $88 | Oct 15, 2026 |
| Raymond James | Strong Buy | $109 | Oct 12, 2026 |
| BMO Capital Markets | Outperform | $98 | Aug 19, 2026 |
| Citigroup | Buy | $75 | May 19, 2026 |
| Goldman Sachs | Neutral | $69 | May 11, 2026 |
| Morgan Stanley | Overweight | $120 | Apr 27, 2026 |
| Barclays | Overweight | $80 | Jan 28, 2026 |
| Canaccord Genuity | Buy | $98 | Jan 20, 2026 |
| Leerink Partners | Market Perform | $60 | Dec 3, 2025 |
Questions about Oppenheimer and BMRN
- What is Oppenheimer's price target for BMRN?
- Oppenheimer's latest stated price target for BioMarin Pharmaceutical Inc. (BMRN) is $98, from its action on Feb 24, 2025.
- What is Oppenheimer's rating on BMRN?
- Oppenheimer rates BMRN Outperform, a bullish rating, as of Feb 24, 2025.
- When did Oppenheimer last change its view on BMRN?
- On Feb 24, 2025, Oppenheimer upgrades to Outperform from Perform, price target $98.
- How does Oppenheimer's BMRN target compare with other analysts?
- Across 9 firms with a BMRN price target in the last 12 months, the median target is $88.
More BMRN rating histories
All Oppenheimer ratingsBMRN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.